Navigation Links
Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Date:10/18/2007

PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that data related to the Company's Amyotrophic Lateral Sclerosis (ALS) drug candidate, AL-02, will be presented at the 18th International Symposium on ALS/MND which will be held on December 1-3, 2007, in Toronto, Canada. The poster presentation by Allitia DiBernardo, M.D. of Massachusetts General Hospital will discuss a pooled analysis of survival data from three randomized, placebo-controlled studies. Results suggest a trend towards increased survival in patients taking AL-02.

The combined analysis examined three trials and included a total of 386 patients. The three trials were conducted by the Northeast ALS Consortium (NEALS), Carolinas Medical Center and Utrecht University. The pooled analysis showed an increase of 1.47-fold in median survival compared to results in patients taking a placebo. Certain portions of these data were presented to the FDA and formed the basis for Avicena's intent to initiate a confirmatory Phase III trial in 2008. This study will evaluate AL-02's effect on the primary endpoint of median survival and secondary endpoints of ALS functional scores.

"These data points support AL-02's positive effect on the survival rate of ALS patients," stated Belinda Tsao-Nivaggioli, Chairman and C.E.O. of Avicena. "We are very encouraged by these results and we will continue to advance AL-02 towards commercialization, as well as our drug candidates for Parkinson's and Huntington's disease. AL-02 will be the Company's third late-stage drug candidate."

ABOUT ALS

ALS is a neurodegenerative disease that attacks the motor neurons of the brain and spinal cord that are responsible for voluntary muscle movement. As these motor neurons degenerate, their ability to send impulses to the muscle fibers is c
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...llnesses caused by subtypes A and B influenza viru...USNewswire/ -- The U.S. Food and Drug Administrati... and older to prevent disease caused by influenza ....newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ,,...agnostics in Siena, Italy, was approved using the ...
(Date:11/27/2009)...wire/ -- ACUO TECHNOLOGIES, developers of high-per...igration tools and services, is pleased to announc...ce has approved a patent application for an "Asset...Acuo Technologies is pleased to add the U.S. paten...neral, the granted patent application broadly prot...
(Date:11/26/2009)...ov. 26 The 2009 Frost & Sulliv...eneric Pharmaceutical Market is presented to Cipla.../www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,...ng criteria were used to benchmark Cipla Medpro,s ...gy and implementation, degree of innovation in bus...
Breaking Medicine Technology:FDA Approves Agriflu Seasonal Influenza Vaccine 2Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Patent challenges reduce pharmaceutical innovation and productivity researchers suggest 59608 1Patent challenges reduce pharmaceutical innovation and productivity researchers suggest 59608 2Patent challenges reduce pharmaceutical innovation and productivity researchers suggest 59608 3Powerhouses in the cell dismantled 14501 1Powerhouses in the cell dismantled 14501 2The future of electricity may be found in environmentally friendly thermoelectric cells 14499 1
... Calif., Oct. 29 Vermillion, Inc.,(OTC Bulletin B...h Quest,Diagnostics to extend the Strategic Allian...2009. This extension will enable the companies to ...tion of two tests, OVA1(TM) and,VASCLIR(TM)., The...ian tumors that,are at high risk of being malignan...
... trial data for Perforomist(TM) Solution presented... Oct. 29 Data from a Phase IIIb,clinical trial de...e),Inhalation Solution nebulized treatment provide...satisfaction compared to albuterol/ipratropium by,...ted today in Philadelphia,at CHEST 2008, the annua...
Other Medicine Technology:Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 2Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 4Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 2Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 3Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 4Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 5Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 6
(Date:11/27/2009)... GSI Group Inc. (Pink She...n technology products and semiconductor systems, t...ny,s shareholders has been scheduled for Friday, A...ng will be announced in due course. As previously...ice from Stephen Bershad, a holder of greater than...
(Date:11/27/2009)...m Replikins Ltd. today issued its latest biochemic...ows that the lethality of the virus has dropped fr...urrent outbreak in the spring of 2009 to resting n...e H1N1 infectivity count, however, remains increas...mber 27, 2009 -- Biotech firm Replikins Ltd., whic...
(Date:11/27/2009)...Newswire-FirstCall/ -- The Gymboree Corporation (N...OO, will present at the NASDAQ OMX 23rd Investor P...n London, England, on Wednesday, December 2, 2009,...dcast of The Gymboree Corporation,s presentation o...m, click on "Our Company" at the bottom of the pag...
(Date:11/27/2009)...ce, Nov. 27 Team Garmin-Slipstream...icated to ethical sporting and developing the next...that it will become Team Garmin-Transitions with t...r of the team. Transitions Optical is the world,s ... the most advanced photochromic technology in the ...
(Date:11/27/2009)...ldings has announced that it has become a national...argest nonprofit organizations dedicated to arthri... Delray Beach, FL (Vocus) Novemb...O), a company specializing in the marketing and re... has announced today that is has become a national...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4
...t chaired by University of Colorado at Boulder Dis...nger research effort on the potential health effec...he global explosion in wireless technology like ce...ear, the report was released Jan 16. The authors ...
...cause of the generosity of,donors and their famili...intz, of Perkiomenville, 2007 was a year that brou...e darkest low. Waiting for a multi-organ,transplan...s later in July, when her,parents received a call ...
...s,Inc. (Nasdaq: PCYC ) today announced that it wi...arter 2008 financial results and achievements on,T...p.m. PDT)., To participate in the conference call...live audio broadcast or the,subsequent archived re...
...Inc.,(Nasdaq: CRDC ) today announced that it will...uarter ended December 31, 2007 on Thursday, Januar...,s management will host a,conference call at 4:30 ...ference call on January 24, 2008 at 4:30 p.m.,East...
...rk City Mayor,Michael Bloomberg, Lance Armstrong a...ona today discussed Lance,s request to the Surgeon... to combat cancer., "This year alone, 1.4 million...an of the Lance Armstrong Foundation,(LAF). "Cance...
...ent of chronic skin disease , , FRIDAY, Ja...jor role in the development of psoriasis, offering...tudy finds. , A team at Wyeth Research, in Cambrid... found injecting IL-22 into the skin of normal mic...
Other Medicine News:Health News:National report calls for more research on health effects of wireless technologies 2Health News:Gift of Life Celebrates Saving Lives and Setting Records in 2007 2Health News:Gift of Life Celebrates Saving Lives and Setting Records in 2007 3Health News:Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008 2Health News:Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer 2Health News:Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer 3
Laser Contact Lens CGRL
Laser 3 mirror Contact Lens 630 L
...apture and management system that acquires extreme...ICG Angiography images. It interfaces with most cu...om any ophthalmic device with video, digital or TW... Retinal Images from non-mydriatic fundus cameras....
...that replaces the old technology, the automated pr...y bringing virtually unlimited charts to the patie...actitioners finger tips. The STIMULi supports man...sion tests and fixation devices in a simple remote...
Medicine Products: